The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 05, 2014

Filed:

Feb. 19, 2010
Applicants:

Yoon-jeong Park, Seoul, KR;

Chong-pyoung Chung, Seoul, KR;

Victor C. Yang, Ann Arbor, MI (US);

Inventors:

Yoon-Jeong Park, Seoul, KR;

Chong-Pyoung Chung, Seoul, KR;

Victor C. Yang, Ann Arbor, MI (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/02 (2006.01); A61P 35/00 (2006.01); C07K 19/00 (2006.01); A61K 47/48 (2006.01); C07K 14/47 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/47 (2013.01); C07K 2319/10 (2013.01); A61K 47/48315 (2013.01); A61K 47/48338 (2013.01); A61K 38/00 (2013.01);
Abstract

The present invention relates to a target-activated cell/tissue-penetrating peptide for delivery of impermeable compounds (Target Activated Cell/tissue Translocation peptide for Impermeable Compound Strategy (TACTICS)), and the use thereof, and more particularly to a target-activated cell/tissue-penetrating peptide, which comprises (a) a protein transduction domain (PTD), (b) a masking domain and (c) a spacer having a cleavage site specific for a target cell/tissue enzyme and is provided with target selectivity so as to penetrate specifically into a target tissue, and to a conjugate of the peptide with a drug or drug-containing particles for imaging or therapeutic applications. Because the target-activated cell/tissue-penetrating peptide has target selectivity, the peptide-drug conjugate exhibits maximized imaging and therapeutic effects, and the non-specific distribution of the conjugate in vivo is inhibited, so that the side effects of the conjugate are minimized, the diagnostic effects of the conjugate are maximized, and the conjugate is useful for the treatment of disease.


Find Patent Forward Citations

Loading…